Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Dow
McKinsey
Express Scripts
Mallinckrodt

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208780

See Plans and Pricing

« Back to Dashboard

NDA 208780 describes ESBRIET, which is a drug marketed by Genentech Inc and is included in two NDAs. It is available from two suppliers. There are twenty-one patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ESBRIET profile page.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.
Summary for 208780
Tradename:ESBRIET
Applicant:Genentech Inc
Ingredient:pirfenidone
Patents:17
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 208780
Generic Entry Date for 208780*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208780
Suppliers and Packaging for NDA: 208780
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ESBRIET pirfenidone TABLET;ORAL 208780 NDA Genentech, Inc. 50242-122 50242-122-05 3 BOTTLE, PLASTIC in 1 CARTON (50242-122-05) > 90 TABLET, COATED in 1 BOTTLE, PLASTIC
ESBRIET pirfenidone TABLET;ORAL 208780 NDA Genentech, Inc. 50242-122 50242-122-06 1 BOTTLE, PLASTIC in 1 CARTON (50242-122-06) > 270 TABLET, COATED in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength267MG
Approval Date:Jan 11, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 15, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Oct 15, 2021
Regulatory Exclusivity Use:TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Patent:  Start TrialPatent Expiration:Mar 28, 2037Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Colorcon
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.